Thomas Davis Net Worth

The estimated Net Worth of Thomas Andrew Davis is at least $754 Thousand dollars as of 4 April 2022. Thomas Davis owns over 1,091 units of Genocea Biosciences Inc stock worth over $0 and over the last 16 years he sold GNCA stock worth over $4,352. In addition, he makes $749,658 as Chief Medical Officer at Genocea Biosciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Thomas Davis GNCA stock SEC Form 4 insiders trading

Thomas has made over 3 trades of the Genocea Biosciences Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 1,091 units of GNCA stock worth $1,364 on 4 April 2022.

The largest trade he's ever made was selling 2,717 units of Genocea Biosciences Inc stock on 15 March 2022 worth over $2,989. On average, Thomas trades about 371 units every 248 days since 2009. As of 4 April 2022 he still owns at least 68,330 units of Genocea Biosciences Inc stock.

You can see the complete history of Thomas Davis stock trades at the bottom of the page.

Thomas Davis biography

Dr. Thomas Andrew Davis M.D. serves as Chief Medical Officer of the Company. Dr. Tom joined Genocea in October 2018 as Chief Medical Officer with over 20 years of academic and industry experience in immuno-oncology and cancer drug development. Most recently, he served as Chief Medical Officer of Gadeta B.V., a Dutch cell therapy company pursuing novel cancer targets from October 2017 to April 2018, where he steered a novel cell therapy technology into first-in human clinical studies. Prior to Gadeta B.V., he served as Chief Medical Officer of Celldex from 2006 to 2017, where he led all aspects of clinical and regulatory development including strategy, tactics, and execution. While at Celldex, Tom actively built and oversaw Clinical Science, Medical Affairs, Safety, Clinical Operations, Statistics, Regulatory Affairs, and Project Management, managed collaborations with large global pharmaceutical partners, and participated in investor relations activities. He also served as Chief Medical Officer at GenVec and as Senior Director of Clinical Science at Medarex.Prior to joining the industry, Tom supervised clinical efforts at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), and worked on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his B.A. in Biophysics from Johns Hopkins, his M.S. in Physiology and his M.D. from Georgetown University, and completed a fellowship in medical oncology at Stanford University.

What is the salary of Thomas Davis?

As the Chief Medical Officer of Genocea Biosciences Inc, the total compensation of Thomas Davis at Genocea Biosciences Inc is $749,658. There are 3 executives at Genocea Biosciences Inc getting paid more, with William Clark having the highest compensation of $1,063,000.

How old is Thomas Davis?

Thomas Davis is 56, he's been the Chief Medical Officer of Genocea Biosciences Inc since 2018. There are 6 older and 12 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.

What's Thomas Davis's mailing address?

Thomas's mailing address filed with the SEC is C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE, MA, 02140.

Insiders trading at Genocea Biosciences Inc

Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.

What does Genocea Biosciences Inc do?

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

Complete history of Thomas Davis stock trades at Celldex Therapeutics and Genocea Biosciences Inc

Genocea Biosciences Inc executives and stock owners

Genocea Biosciences Inc executives and other stock owners filed with the SEC include:

• William Clark,
  President, Chief Executive Officer, Director
• William D. Clark M.B.A.,
  Pres, CEO & Director
• Girish Aakalu,
  Chief Business Officer
• Thomas Davis,
  Chief Medical Officer
• Jessica Flechtner,
  Chief Scientific Officer
• Dr. Thomas A. Davis,
  Chief Medical Officer
• Dr. Girish N. Aakalu Ph.D.,
  Chief Bus. Officer
• Katrine Bosley,
  Independent Director
• Kenneth Bate,
  Independent Chairman of the Board
• George Siber,
  Independent Director
• Michael Higgins,
  Independent Director
• Ronald Cooper,
  Independent Director
• Ali Behbahani,
  Independent Director
• Gisela Schwab,
  Director
• Narinderjeet Singh,
  Senior Vice President - Pharmaceutical Sciences and Manufacturing
• Diantha Duvall,
  Chief Financial Officer
• Dr. Jessica Baker Flechtner,
  Chief Scientific Officer
• Diantha Duvall,
  CFO & Sec.
• Dr. Raymond D. Stapleton Jr.,
  Exec. VP of Pharmaceutical Sciences & Manufacturing
• Jacquelyn L. Sumer,
  Chief Legal & Compliance Officer
• Kevin Bitterman,
  Director
• Jonathan Poole,
  Chief Financial Officer
• Seth V Hetherington,
  Chief Medical Officer
• Paul Giannasca,
  VP of Development
• Stephen J Hoffman,
  Director
• Howard Mayer,
  Director
• Eric S Hoffman,
  Chief Business Officer
• Venture Management Co. V, L...,
  
• John Lunger,
  Director
• Michael Alfieri,
  Principle Financial Officer
• Derek M Meisner,
  SENIOR VP AND GENERAL COUNSEL
• Pamela Carroll,
  SVP IMMUNO-ONCOLOGY
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Scott D Sandell,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Peter W. Sonsini,
  10% owner
• Joshua Makower,
  10% owner
• Carmen Chang,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 16, L...,
  
• Jacquelyn L Sumer,
  CHIEF LEGAL & COMPLIANCE OFF
• Robert E Jr Farrell,
  VP of Finance & Administration
• Venture Management Co. V, L...,
  
• Capital Management, Llc Lux...,
  
• Simeon George,
  Director
• & Johnson Johnson & Johnson...,
  
• Plc Gsk,
  10% owner
• Paul Edward Walker,
  10% owner
• Jennifer Lyn Herron,
  Director
• Raymond D Jr Stapleton,
  CHIEF TECHNOLOGY OFFICER